<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Physiology of gastrin</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Physiology of gastrin</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Physiology of gastrin</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Rodger A Liddle, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">J Thomas Lamont, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Shilpa Grover, MD, MPH, AGAF</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Mar 20, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Gastrin is the major hormonal regulator of gastric acid secretion [<a href="#rid1">1</a>]. Its discovery in 1905 was based upon its profound effect on meal-stimulated acid secretion, making it one of the first hormones to be described [<a href="#rid2">2</a>]. The study of gastrin accelerated with the isolation and characterization of the peptide in 1964, after which it was found to promote growth of the gastric mucosa and have proliferative effects on cells that express the gastrin receptor [<a href="#rid3">3</a>]. The cloning and characterization of the gastrin receptor has provided keen insights into physiology and pathophysiology of gastrin [<a href="#rid4">4</a>].</p><p>This topic will review the physiology of gastrin. Zollinger-Ellison syndrome and the physiology of gastric acid secretion are discussed in detail elsewhere. (See  <a class="medical medical_review" href="/d/html/2627.html" rel="external">"Zollinger-Ellison syndrome (gastrinoma): Clinical manifestations and diagnosis"</a> and  <a class="medical medical_review" href="/d/html/2584.html" rel="external">"Management and prognosis of the Zollinger-Ellison syndrome (gastrinoma)"</a> and  <a class="medical medical_review" href="/d/html/33.html" rel="external">"Physiology of gastric acid secretion"</a>.)</p><p class="headingAnchor" id="H5"><span class="h1">GASTRIN PHYSIOLOGY</span></p><p class="headingAnchor" id="H2646458744"><span class="h2">Molecular forms</span><span class="headingEndMark"> — </span>Human gastrin is the product of a single gene located on chromosome 17. The active hormone is generated from a precursor peptide "preprogastrin" (<a class="graphic graphic_figure graphicRef140570" href="/d/graphic/140570.html" rel="external">figure 1</a>). Human preprogastrin contains 101 amino acids (AA) including a signal peptide (21 AA), spacer sequence (37 AA), gastrin component (34 AA), and a 9 AA extension segment at the carboxyl terminus. The enzymatic processing of preprogastrin produces all of the known physiologically active forms of gastrin.</p><p>Preprogastrin is processed into progastrin and gastrin peptide fragments of various sizes by sequential enzymatic cleavage (<a class="graphic graphic_figure graphicRef140570" href="/d/graphic/140570.html" rel="external">figure 1</a>). Like other hormones, gastrin is synthesized on rough endoplasmic reticulum, processed in the Golgi apparatus, and packaged in secretory granules, where final modifications occur [<a href="#rid5">5</a>]. In endocrine cells of the gut (enteroendocrine cells), the glycine residue at the carboxyl terminus is cleaved and the terminus is amidated to form the mature gastrin peptide.</p><p>Two major forms of gastrin are secreted (G-17 and G-34), although larger N-terminal extended forms (eg, G-71) and smaller forms (eg, G-6) exist. The common feature of all gastrins is an amidated tetrapeptide (Try-Met-Asp-Phe-NH2) at the carboxyl terminus that imparts full biological activity. Modification by sulfation at tyrosine residues produces alternative gastrin forms. The circulating half-life of gastrin is affected by the size of the various molecular forms. The full physiologic response is determined by the presence of the biologically active tetrapeptide and the time available for receptor interaction. (See  <a class="medical medical_review" href="/d/html/2534.html" rel="external">"Overview of gastrointestinal peptides in health and disease"</a>.)</p><p>Gastrin can be ectopically expressed in tumors. However, because these cells lack secretory vesicles, prohormone convertases, and amidating enzymes, the main forms of gastrin secreted are progastrins including glycine-extended gastrin. These forms of gastrin may have growth-promoting effects on certain tumors. (See <a class="local">'Unclear clinical implications of hypergastrinemia'</a> below.)</p><p class="headingAnchor" id="H1602909905"><span class="h2">Tissue distribution</span><span class="headingEndMark"> — </span>The vast majority of gastrin is produced in gastrin-expressing cells (G cells) of the gastric antrum [<a href="#rid6">6</a>]. Much smaller amounts of gastrin are produced in other regions of the gastrointestinal tract including the nonantral stomach, duodenum, jejunum, ileum, and pancreas. Gastrin has also been found outside of the gastrointestinal tract including the brain, adrenal glands, respiratory tract, and reproductive organs, although its biological role in these sites is unknown (<a class="graphic graphic_table graphicRef140571" href="/d/graphic/140571.html" rel="external">table 1</a>).</p><p class="headingAnchor" id="H2643454466"><span class="h2">Regulation of gastrin</span><span class="headingEndMark"> — </span>Gastrin release is profoundly influenced by the pH of the stomach. Fasting and increased gastric acid in the stomach inhibit its release, whereas a high gastric pH provides a strong stimulus for its secretion. The G cells are tightly regulated by two counterbalancing transmitters, the neurotransmitter gastrin-releasing peptide (GRP) and the paracrine regulator somatostatin, which exert stimulatory and inhibitory effects, respectively. Physiological regulation of gastrin secretion is highest when nutrients are in direct contact with G cells. Consequently, diversion of food from the antrum of the stomach, as with Roux-en-Y gastric bypass, has been associated with low blood levels of gastrin [<a href="#rid7">7</a>]. </p><p>In fasting humans, normal plasma concentrations of gastrin are 10 to 30 pmol/L and consist primarily of G-34, which has a circulating half-life five times longer than G-17.<sup> </sup>After a meal consisting of a mixture of protein, fat, and carbohydrates, peak gastrin levels increase two- to threefold by 30 to 60 minutes and consist primarily of G-17 [<a href="#rid8">8</a>]. Thus, gastrin circulates as a mixture of peptides ranging from G-17 to G-71, although G-17 and G-34 predominate [<a href="#rid9">9</a>]. Standard commercial antibodies used in clinical assays bind both G-17 and G-34.  </p><p class="headingAnchor" id="H118890676"><span class="h2">Gastrin receptors</span><span class="headingEndMark"> — </span>The receptors for gastrin and cholecystokinin (CCK) share considerable sequence homology and constitute the CCK/gastrin receptor family. Gastrin binds to the CCK2 receptor (formerly known as the CCK-B or gastrin receptor). CCK2 has equal affinity for gastrin and CCK peptides, which have an identical pentapeptide terminal sequence [<a href="#rid4">4</a>]. The CCK2/gastrin receptor is found on parietal cells and enterochromaffin-like (ECL) cells in the stomach, in the brain, and on pancreatic islet cells. The CCK1 receptor is abundant in the pancreas and gallbladder and has a 1000-fold higher affinity for CCK than for gastrin.  </p><p>Gastrin receptors have also been found on somatostatin-secreting D cells. However, this receptor is CCK1, which has much greater affinity for CCK than for gastrin [<a href="#rid10">10</a>]. This difference in receptor affinity may explain why gastrin is so much more effective as a stimulant of acid secretion, while CCK induces greater release of the inhibitor somatostatin [<a href="#rid11">11</a>]. Knockout mice genetically engineered to be deficient in CCK2 receptors have low acid secretion, while double knockout mice (deficient in both CCK1 and CCK2 receptors) have robust acid secretion in response to vagal stimulation or exogenous histamine [<a href="#rid12">12</a>]. These findings indicate that CCK1 receptors exert inhibitory effects on acid secretion in vivo and are likely mediated by release of endogenous somatostatin. </p><p>The localization of the receptors responsible for trophic actions of gastrin remains uncertain; the primary receptor appears to be on the ECL cell, although receptors may also be present on gastric stem cells.</p><p>Complex mechanisms control gastrin release from the antral G cells. </p><p class="bulletIndent1"><span class="glyph">●</span>Gastric distension impacts gastrin secretion, and the effect varies with the degree of distension [<a href="#rid13">13</a>]. Low-grade distention activates vasoactive intestinal peptide neurons, which stimulate somatostatin release and inhibit gastrin secretion. Higher grade distention causes cholinergic activation, which reverses the pattern to one of increased gastrin and reduced somatostatin secretion.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Dietary amino acids induce gastrin release by directly acting on G cells and indirectly through activation of both cholinergic neurons and GRP neurons [<a href="#rid14">14</a>]. GRP released from mucosal nerves directly stimulates the G cell [<a href="#rid15">15</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Gastrin inhibits its own secretion by enhancing the secretion of somatostatin [<a href="#rid14">14</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Hypercalcemia stimulates gastrin secretion through activation of the calcium-sensing receptor on G cells [<a href="#rid16">16</a>].</p><p></p><p class="headingAnchor" id="H3744501379"><span class="h2">Biologic actions</span></p><p class="headingAnchor" id="H3982711833"><span class="h3">Gastric acid secretion</span><span class="headingEndMark"> — </span>Gastrin is a primary physiologic mediator of gastric acid secretion and is the major hormonal regulator of the secretory response to a protein meal. Gastric acid secretion is influenced by the central, peripheral, and enteric nervous systems mediated by the neurocrine transmitter GRP and neurotransmitter acetylcholine.    </p><p>The major cellular determinants of acid secretion involve the antral gastrin-secreting G cell, the ECL cell of the stomach that secretes histamine, and the somatostatin-secreting D cell. The acid-secreting parietal cell possesses receptors for acetylcholine, histamine, and gastrin. Although activation of all three receptors can stimulate acid secretion, the most important mechanism of acid release occurs via stimulation of the ECL cell to secrete histamine, which in turn stimulates the parietal cell [<a href="#rid17">17,18</a>]. The ECL cell receives stimulatory signals from gastrin and inhibitory signals from somatostatin (<a class="graphic graphic_figure graphicRef140294" href="/d/graphic/140294.html" rel="external">figure 2</a>). Somatostatin also provides inhibitory signals to antral G cells and, therefore, inhibits gastric acid secretion.</p><p class="headingAnchor" id="H113723616"><span class="h3">Other biologic effects</span><span class="headingEndMark"> — </span>Gastrin is also the best identified trophic regulator of parietal cell mass in humans. This relationship is evidenced by the presence of gastric hypertrophy in gastrinoma patients who have chronic exposure to elevated gastrin levels (<a class="graphic graphic_picture graphicRef78549" href="/d/graphic/78549.html" rel="external">picture 1</a>), and atrophy of the parietal cell mass with antrectomy, which decreases gastrin levels. Gastrin activates several mitogenic pathways, including epidermal growth factor receptor signaling, phosphoinositide 3-kinase (PI3K), and MAPK activity [<a href="#rid19">19</a>].</p><p>Gastrin is the major hormonal regulator of pepsinogen secretion from gastric chief cells [<a href="#rid20">20</a>].</p><p>The CCK2 receptor can be found on pancreatic islet cells, and hypergastrinemia has been associated with islet cell hyperplasia and enhanced insulin secretion [<a href="#rid21">21</a>]. In animals, coadministration of gastrin and glucagon-like peptide-1 can restore normoglycemia in diabetic mice, suggesting that gastrin may have incretin-like effects [<a href="#rid21">21</a>]. Gastrin acting on CCK2 receptors in the proximal tubule exerts natriuretic effects [<a href="#rid22">22</a>]. (See  <a class="medical medical_review" href="/d/html/1772.html" rel="external">"Glucagon-like peptide 1-based therapies for the treatment of type 2 diabetes mellitus", section on 'Gastrointestinal peptides'</a>.)</p><p class="headingAnchor" id="H7"><span class="h1">HYPERGASTRINEMIA</span></p><p class="headingAnchor" id="H2847896493"><span class="h2">Causes of hypergastrinemia</span><span class="headingEndMark"> — </span>Since gastrin secretion is strongly influenced by intraluminal gastric pH, it is helpful to interpret hypergastrinemia in relation to gastric acid production. Hypergastrinemia is observed in a number of settings, of which use of acid-suppressive medications and chronic atrophic gastritis are by far the most common (<a class="graphic graphic_table graphicRef60819" href="/d/graphic/60819.html" rel="external">table 2</a>). In these conditions, gastric acid is reduced resulting in alkalinization of gastric contents. Sensing the elevated pH, G cells secrete gastrin. Hypoacidity also accounts for the increased plasma gastrin levels often associated with <em>Helicobacter pylori</em> infection [<a href="#rid23">23</a>]. Less common causes of hypergastrinemia associated with reduced acid production are renal insufficiency and truncal vagotomy.</p><p>Secretion of gastrin by a gastrinoma (Zollinger-Ellison syndrome) is a rare but important cause of hypergastrinemia (<a class="graphic graphic_picture graphicRef78549" href="/d/graphic/78549.html" rel="external">picture 1</a>). Most patients with Zollinger-Ellison syndrome have serum gastrin concentrations between 150 and 1000 pg/mL (71 and 475 pmol/L). In this condition, ectopic gastrin secretion is independent of gastric pH, thus circulating gastrin levels are high despite excessive gastric acid production (<a class="graphic graphic_table graphicRef60819" href="/d/graphic/60819.html" rel="external">table 2</a>). (See  <a class="medical medical_review" href="/d/html/2627.html" rel="external">"Zollinger-Ellison syndrome (gastrinoma): Clinical manifestations and diagnosis"</a>.)</p><p>The highest gastrin levels (&gt;1000 pg/mL), although rare, are seen with gastrin-secreting tumors or chronic atrophic gastritis accompanying pernicious anemia. Modest elevations in serum gastrin (approximately 200 to 400 pg/mL) are much more common and are often due to acid-suppressive medications (ie, H2 blockers or proton pump inhibitors [PPIs]) or <em>H. pylori</em>-associated gastritis.</p><p>Elevated gastrin levels are often seen following small bowel resection due to the loss of enterogastrones (hormones such as <a class="drug drug_general" data-topicid="10259" href="/d/drug information/10259.html" rel="external">secretin</a> that tend to inhibit gastric acid secretion). With loss of enterogastrones, there is an increase in gastric acid secretion and gastric pH is low. </p><p>Other rare causes of achlorhydria-associated hypergastrinemia may occur in the absence of gastritis. For example, impaired potassium secretion into the gastric lumen can reduce hydrogen-potassium proton pump activity on the apical surface of parietal cells, resulting in low acid secretion [<a href="#rid24">24</a>]. Patients with Jervell and Lange-Nielsen syndrome caused by mutations in the potassium channel gene <em>KCNQ1</em> not only have cardiac arrhythmias due to QT prolongation but have gastric achlorhydria, iron deficiency anemia, and hypergastrinemia as a consequence of impaired potassium ion secretion [<a href="#rid25">25</a>].</p><p class="headingAnchor" id="H8"><span class="h2">Unclear clinical implications of hypergastrinemia</span><span class="headingEndMark"> — </span>The clinical significance of chronic elevation in serum gastrin levels (as may be seen in patients taking PPIs long-term) is uncertain. Gastrin receptors have been detected on a variety of tumor cells, and gastrin has trophic effects on the stomach and intestine, suggesting that it may have a role in the development of gastrointestinal malignancies [<a href="#rid26">26,27</a>]. The degree to which this might contribute to oncogenesis has not been defined. Gastrin has both antiapoptotic and mitogenic effects in various gastrointestinal malignancies. These effects are mediated by CCK2, which is expressed in human gastric neuroendocrine neoplasms and gastric, pancreatic,<sup> </sup>and colorectal adenocarcinomas [<a href="#rid28">28-31</a>].</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Gastric adenocarcinoma</strong> – Gastric cancer cells express CCK2, which appears to mediate the direct effects of gastrin. The ability of gastrin to stimulate cancer has been demonstrated on gastric cancer cells in vitro and human gastric cancer xenografts. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Fundic gland polyps</strong> – Long-term treatment with PPIs has been associated with the development of gastric fundic polyps and hyperplasia of the oxyntic mucosa. The clinical significance of these observations is uncertain, and their pathogenesis is incompletely understood [<a href="#rid32">32</a>]. Infection with <em>H. pylori</em> may have a role since gastrin has a growth-promoting effect [<a href="#rid33">33</a>]. (See  <a class="medical medical_review" href="/d/html/2518.html" rel="external">"Gastric polyps", section on 'Fundic gland polyps'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Gastric carcinoid</strong> <strong>tumors</strong> – Although prolonged hypergastrinemia from potent antisecretory therapy has been associated with the development of enterochromaffin-like (ECL) cell carcinoid tumors in rodents, the incidence of gastric carcinoid tumors is low in adults exposed to short-term or periodic acid suppression. The risk of developing a gastric carcinoid is greatest in patients treated with PPI drugs for more than 10 years and those with chronic <em>H. pylori</em> infection and gastric atrophy [<a href="#rid34">34</a>]. The role of gastrin appears to be central in the development of ECL carcinoids associated with atrophic gastritis since the gastrin receptor antagonist netazepide has been shown to induce regression of these carcinoids [<a href="#rid35">35</a>]. (See  <a class="medical medical_review" href="/d/html/5.html" rel="external">"Proton pump inhibitors: Overview of use and adverse effects in the treatment of acid related disorders", section on 'Hypergastrinemia'</a>.)</p><p></p><p class="bulletIndent1">Studies in patients with gastrinoma and pernicious anemia who develop carcinoids suggest that carcinoid tumor formation requires not only hypergastrinemia but another cofactor, such as loss of the tumor suppressor gene, menin (the genetic defect in multiple endocrine neoplasia type 1 [MEN-1]), or overexpression of a tumor growth promoter such as BCL-2, which occurs in the setting of chronic inflammation and atrophic gastritis [<a href="#rid36">36</a>]. This hypothesis is supported by the observation that carcinoid tumors have been reported in up to 30 percent of patients with MEN-1 and 5 percent of patients with atrophic gastritis and pernicious anemia. However, carcinoid tumors occur in only 1 percent of patients with sporadic gastrinomas [<a href="#rid37">37,38</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Colon cancer</strong> – It remains controversial whether circulating gastrin has a significant role in the development of human colon cancer. Gastrin has been implicated in colon cancer based upon laboratory and epidemiologic evidence [<a href="#rid39">39-43</a>]. Elevated gastrin levels were associated with an increased risk of colorectal malignancy [<a href="#rid41">41</a>], although this association may be due to the production of gastrin by most colon cancers [<a href="#rid44">44</a>]. However, an increased rate of colon cancer has not been observed in patients with gastrinoma, pernicious anemia, or in those taking acid-suppressive medications [<a href="#rid45">45</a>]. It is likely that chronic hypergastrinemia by itself is not carcinogenic, but its proliferative effects may expand the pool of cells that could be at risk for carcinogenesis in susceptible patients. One group of patients at risk may be those infected with <em>H. pylori</em> [<a href="#rid41">41,46</a>]. </p><p></p><p class="bulletIndent1">The following observations illustrate some of the laboratory findings:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Gastrin increases the proliferation of colon cancer cell lines and the tumor burden in mice with colon cancer [<a href="#rid47">47</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Gastrin and glycine-extended gastrin have growth-promoting effects on human colon cancer in vivo and in vitro [<a href="#rid48">48</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>A specific inhibitor of glycine-extended gastrin inhibited the growth of human colon cancer, suggesting that receptor blockade may be a strategy for treating patients with colon cancer [<a href="#rid49">49</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Progastrin, glycine-extended gastrin, and amidated gastrin have been detected in cell extracts of gastrointestinal malignancies, suggesting that gastrin may be an autocrine or paracrine growth regulator [<a href="#rid50">50-52</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Immunostaining reveals that 80 to 90 percent of colon polyps contain gastrin [<a href="#rid53">53</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Gastrin inhibits apoptosis [<a href="#rid54">54</a>] and enhances angiogenesis [<a href="#rid55">55</a>].</p><p></p><p class="bulletIndent1">Although gastrin could be a potential target in the treatment of colorectal cancer, receptor antagonists and antisecretory agents have been ineffective [<a href="#rid44">44</a>].  </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pancreatic cancer</strong> – The CCK2 receptor is rare in a normal pancreas but appears in pancreatic intraepithelial neoplasia (PanIN) lesions of the pancreas and is highly expressed in pancreatic adenocarcinoma [<a href="#rid56">56</a>]. A role for gastrin in the proliferation of pancreatic cancer cells is supported by the observation that growth of cultured human pancreatic cancer cells can be inhibited by antisense oligonucleotides to gastrin [<a href="#rid57">57</a>] and activation of CCK2 potentiates cancer growth [<a href="#rid27">27</a>]. This effect is believed to be autocrine or paracrine since gastrin and its messenger RNA have been identified in cancers of the human pancreas [<a href="#rid58">58</a>]. Gastrin has also been implicated in a mouse model of pancreatic cancer metastasis [<a href="#rid59">59</a>].</p><p></p><p class="headingAnchor" id="H13"><span class="h1">CLINICAL APPLICATIONS OF GASTRIN</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pentagastrin </strong>– The gastrin analog, pentagastrin, has been used clinically to stimulate histamine and gastric acid secretion in diagnostic tests of acid secretory capacity [<a href="#rid60">60</a>]. </p><p></p><p class="bulletIndent1">Parafollicular C cells of the thyroid gland and medullary thyroid carcinoma are neural crest in origin and secrete calcitonin, which regulates calcium homeostasis. By virtue of their expression of CCK2 receptors, C cells and medullary carcinomas secrete calcitonin in response to exogenous pentagastrin. This response is sufficiently sensitive that intravenous injection of pentagastrin is used as a provocative test in the biochemical diagnosis of medullar thyroid cancers [<a href="#rid61">61,62</a>]. (See  <a class="medical medical_review" href="/d/html/2610.html" rel="external">"VIPoma: Clinical manifestations, diagnosis, and management"</a> and  <a class="medical medical_review" href="/d/html/7848.html" rel="external">"Medullary thyroid cancer: Clinical manifestations, diagnosis, and staging", section on 'Evaluation'</a>.)</p><p></p><p class="bulletIndent1">Pentagastrin has been used to provoke symptoms and stimulate 5-hydroxytryptamine release in patients with carcinoid syndrome [<a href="#rid63">63</a>]. Profound responses in some patients require that the test be conducted under careful medical monitoring [<a href="#rid64">64</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Gastrin receptor antagonists </strong>– Gastrin receptor antagonists have the theoretical advantage of blocking gastrin-induced gastric acid secretion, while obviating concern for the trophic effects related to hypergastrinemia. In addition, they could have a role in the treatment and prevention of certain gastrointestinal malignancies that express gastrin receptors. In one study, a gastrin receptor antagonist reduced tumor size in patients with neuroendocrine tumors associated with autoimmune atrophic gastritis [<a href="#rid65">65</a>]. Other ongoing or recently completed clinical trials are evaluating gastrin antagonists on gastric carcinoids and Barrett's esophagus. Other than investigative studies, gastrin antagonists have not been approved for clinical use. (See <a class="local">'Hypergastrinemia'</a> above.)  </p><p></p><p class="headingAnchor" id="H68312172"><span class="h1">SUMMARY</span></p><p class="bulletIndent1"><span class="glyph">●</span>Human gastrin is the product of a single gene located on chromosome 17. The active hormone is generated from a precursor peptide "preprogastrin" (<a class="graphic graphic_figure graphicRef140570" href="/d/graphic/140570.html" rel="external">figure 1</a>). (See <a class="local">'Molecular forms'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The vast majority of gastrin is produced in hormone-producing cells of the gastric antrum (G cells). Much smaller amounts of gastrin are produced in other regions of the gastrointestinal tract including the nonantral stomach, duodenum, jejunum, ileum, and pancreas. Gastrin has also been found outside of the gastrointestinal tract including the brain, adrenal glands, respiratory tract, and reproductive organs, although its biological role in these sites is unknown (<a class="graphic graphic_table graphicRef140571" href="/d/graphic/140571.html" rel="external">table 1</a>). (See <a class="local">'Tissue distribution'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The receptors for gastrin and cholecystokinin (CCK) are related and constitute the CCK/gastrin receptor family. The CCK1 receptor is abundant in the pancreas and gallbladder and has a 1000-fold higher affinity for CCK than for gastrin. The CCK2/gastrin receptor is found on parietal cells and enterochromaffin-like (ECL) cells in the stomach, in the brain, and on pancreatic islet cells.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Gastrin is released from G cells into the circulation in response to a meal or to a high gastric pH. The G cells are tightly regulated by two counterbalancing hormones, gastrin-releasing peptide and somatostatin, which exert stimulatory and inhibitory effects, respectively. (See <a class="local">'Gastrin physiology'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Gastrin is a primary physiologic mediator of gastric acid secretion. Gastrin stimulates ECL cells, which then secrete histamine, which in turn stimulates parietal cells to secrete acid (<a class="graphic graphic_figure graphicRef140294" href="/d/graphic/140294.html" rel="external">figure 2</a>). (See <a class="local">'Gastrin physiology'</a> above.) </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The clinical significance of chronic elevation in serum gastrin levels (as may be seen in patients taking proton pump inhibitors long-term) is uncertain. Gastrin receptors have been detected on a variety of tumor cells, and gastrin has trophic effects on the stomach and intestine, suggesting that it may have a role in the development of gastrointestinal malignancies. However, the degree to which this might contribute to oncogenesis has not been defined. (See <a class="local">'Unclear clinical implications of hypergastrinemia'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The gastrin analog, pentagastrin, has been used clinically to stimulate histamine and gastric acid secretion in diagnostic tests of acid secretory capacity. This test has been used to assess the extent of surgical vagotomy and to screen for thyroid C-cell hyperplasia and medullary carcinomas. (See  <a class="medical medical_review" href="/d/html/2610.html" rel="external">"VIPoma: Clinical manifestations, diagnosis, and management"</a> and  <a class="medical medical_review" href="/d/html/7848.html" rel="external">"Medullary thyroid cancer: Clinical manifestations, diagnosis, and staging", section on 'Evaluation'</a>.)</p><p></p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Schubert ML, Rehfeld JF. Gastric Peptides-Gastrin and Somatostatin. Compr Physiol 2019; 10:197.</a></li><li><a class="nounderline abstract_t">Edkins JS. On the chemical mechanism of gastric secretion. Proc R Soc Lond B Biol Sci 1905; 76:376.</a></li><li><a class="nounderline abstract_t">GREGORY RA, TRACY HJ. THE CONSTITUTION AND PROPERTIES OF TWO GASTRINS EXTRACTED FROM HOG ANTRAL MUCOSA. Gut 1964; 5:103.</a></li><li><a class="nounderline abstract_t">Kopin AS, Lee YM, McBride EW, et al. Expression cloning and characterization of the canine parietal cell gastrin receptor. Proc Natl Acad Sci U S A 1992; 89:3605.</a></li><li><a class="nounderline abstract_t">Rehfeld JF. Processing of precursors of gastroenteropancreatic hormones: diagnostic significance. J Mol Med (Berl) 1998; 76:338.</a></li><li><a class="nounderline abstract_t">Rehfeld JF. The new biology of gastrointestinal hormones. Physiol Rev 1998; 78:1087.</a></li><li><a class="nounderline abstract_t">Meek CL, Lewis HB, Reimann F, et al. The effect of bariatric surgery on gastrointestinal and pancreatic peptide hormones. Peptides 2016; 77:28.</a></li><li class="breakAll">Chao C, Hellmich MR. Gastrointestinal peptides: gastrin, cholecystokinin, somatostatin and ghrelin. In: Physiology of the Gastrointestinal Tract, 5th ed, Johnson LR (Ed), Academic Press, 2012. p.115.</li><li><a class="nounderline abstract_t">Rehfeld JF. The art of measuring gastrin in plasma: a dwindling diagnostic discipline? Scand J Clin Lab Invest 2008; 68:353.</a></li><li><a class="nounderline abstract_t">Soll AH, Amirian DA, Park J, et al. Cholecystokinin potently releases somatostatin from canine fundic mucosal cells in short-term culture. Am J Physiol 1985; 248:G569.</a></li><li><a class="nounderline abstract_t">Schmidt WE, Schmitz F. Cellular localization of cholecystokinin receptors as the molecular basis of the periperal regulation of acid secretion. Pharmacol Toxicol 2002; 91:351.</a></li><li><a class="nounderline abstract_t">Chen D, Friis-Hansen L, Håkanson R, Zhao CM. Genetic dissection of the signaling pathways that control gastric acid secretion. Inflammopharmacology 2005; 13:201.</a></li><li><a class="nounderline abstract_t">Schubert ML, Makhlouf GM. Gastrin secretion induced by distention is mediated by gastric cholinergic and vasoactive intestinal peptide neurons in rats. Gastroenterology 1993; 104:834.</a></li><li><a class="nounderline abstract_t">Schubert ML, Makhlouf GM. Neural, hormonal, and paracrine regulation of gastrin and acid secretion. Yale J Biol Med 1992; 65:553.</a></li><li><a class="nounderline abstract_t">Seensalu R, Avedian D, Barbuti R, et al. Bombesin-induced gastrin release from canine G cells is stimulated by Ca2+ but not by protein kinase C, and is enhanced by disruption of rho/cytoskeletal pathways. J Clin Invest 1997; 100:1037.</a></li><li><a class="nounderline abstract_t">Feng J, Petersen CD, Coy DH, et al. Calcium-sensing receptor is a physiologic multimodal chemosensor regulating gastric G-cell growth and gastrin secretion. Proc Natl Acad Sci U S A 2010; 107:17791.</a></li><li><a class="nounderline abstract_t">Hersey SJ, Sachs G. Gastric acid secretion. Physiol Rev 1995; 75:155.</a></li><li><a class="nounderline abstract_t">Sachs G, Prinz P. Gastric enterochromaffin-like cells and the regulation of acid secretion. News in Physiological Sci 1996; 11:57.</a></li><li><a class="nounderline abstract_t">Duan S, Rico K, Merchant JL. Gastrin: From Physiology to Gastrointestinal Malignancies. Function (Oxf) 2022; 3:zqab062.</a></li><li><a class="nounderline abstract_t">Chu S, Schubert ML. Gastric secretion. Curr Opin Gastroenterol 2013; 29:636.</a></li><li><a class="nounderline abstract_t">Rehfeld JF. Incretin physiology beyond glucagon-like peptide 1 and glucose-dependent insulinotropic polypeptide: cholecystokinin and gastrin peptides. Acta Physiol (Oxf) 2011; 201:405.</a></li><li><a class="nounderline abstract_t">Chen Y, Asico LD, Zheng S, et al. Gastrin and D1 dopamine receptor interact to induce natriuresis and diuresis. Hypertension 2013; 62:927.</a></li><li><a class="nounderline abstract_t">Calam J, Gibbons A, Healey ZV, et al. How does Helicobacter pylori cause mucosal damage? Its effect on acid and gastrin physiology. Gastroenterology 1997; 113:S43.</a></li><li><a class="nounderline abstract_t">Song P, Groos S, Riederer B, et al. KCNQ1 is the luminal K+ recycling channel during stimulation of gastric acid secretion. J Physiol 2009; 587:3955.</a></li><li><a class="nounderline abstract_t">Winbo A, Sandström O, Palmqvist R, Rydberg A. Iron-deficiency anaemia, gastric hyperplasia, and elevated gastrin levels due to potassium channel dysfunction in the Jervell and Lange-Nielsen Syndrome. Cardiol Young 2013; 23:325.</a></li><li><a class="nounderline abstract_t">Clerc P, Dufresne M, Saillan C, et al. Differential expression of the CCK-A and CCK-B/gastrin receptor genes in human cancers of the esophagus, stomach and colon. Int J Cancer 1997; 72:931.</a></li><li><a class="nounderline abstract_t">de Weerth A, von Schrenck T, Löhr M, et al. Human pancreatic cancer cell lines express the CCKB receptor. Hepatogastroenterology 1999; 46:472.</a></li><li><a class="nounderline abstract_t">Smith JP, Nadella S, Osborne N. Gastrin and Gastric Cancer. Cell Mol Gastroenterol Hepatol 2017; 4:75.</a></li><li><a class="nounderline abstract_t">Mjønes P, Nordrum IS, Sørdal Ø, et al. Expression of the Cholecystokinin-B Receptor in Neoplastic Gastric Cells. Horm Cancer 2018; 9:40.</a></li><li><a class="nounderline abstract_t">Goetze JP, Nielsen FC, Burcharth F, Rehfeld JF. Closing the gastrin loop in pancreatic carcinoma: coexpression of gastrin and its receptor in solid human pancreatic adenocarcinoma. Cancer 2000; 88:2487.</a></li><li><a class="nounderline abstract_t">Hellmich MR, Rui XL, Hellmich HL, et al. Human colorectal cancers express a constitutively active cholecystokinin-B/gastrin receptor that stimulates cell growth. J Biol Chem 2000; 275:32122.</a></li><li><a class="nounderline abstract_t">el-Zimaity HM, Jackson FW, Graham DY. Fundic gland polyps developing during omeprazole therapy. Am J Gastroenterol 1997; 92:1858.</a></li><li><a class="nounderline abstract_t">Chowers MY, Keller N, Tal R, et al. Human gastrin: a Helicobacter pylori--specific growth factor. Gastroenterology 1999; 117:1113.</a></li><li><a class="nounderline abstract_t">McCarthy DM. Proton Pump Inhibitor Use, Hypergastrinemia, and Gastric Carcinoids-What Is the Relationship? Int J Mol Sci 2020; 21.</a></li><li><a class="nounderline abstract_t">Waldum HL, Hauso Ø, Fossmark R. The regulation of gastric acid secretion - clinical perspectives. Acta Physiol (Oxf) 2014; 210:239.</a></li><li><a class="nounderline abstract_t">Cadiot G, Laurent-Puig P, Thuille B, et al. Is the multiple endocrine neoplasia type 1 gene a suppressor for fundic argyrophil tumors in the Zollinger-Ellison syndrome? Gastroenterology 1993; 105:579.</a></li><li><a class="nounderline abstract_t">Bordi C, D'Adda T, Azzoni C, et al. Hypergastrinemia and gastric enterochromaffin-like cells. Am J Surg Pathol 1995; 19 Suppl 1:S8.</a></li><li><a class="nounderline abstract_t">Gibril F, Schumann M, Pace A, Jensen RT. Multiple endocrine neoplasia type 1 and Zollinger-Ellison syndrome: a prospective study of 107 cases and comparison with 1009 cases from the literature. Medicine (Baltimore) 2004; 83:43.</a></li><li><a class="nounderline abstract_t">Nakata H, Wang SL, Chung DC, et al. Oncogenic ras induces gastrin gene expression in colon cancer. Gastroenterology 1998; 115:1144.</a></li><li><a class="nounderline abstract_t">Renga M, Brandi G, Paganelli GM, et al. Rectal cell proliferation and colon cancer risk in patients with hypergastrinaemia. Gut 1997; 41:330.</a></li><li><a class="nounderline abstract_t">Thorburn CM, Friedman GD, Dickinson CJ, et al. Gastrin and colorectal cancer: a prospective study. Gastroenterology 1998; 115:275.</a></li><li><a class="nounderline abstract_t">Grabowska AM, Watson SA. Role of gastrin peptides in carcinogenesis. Cancer Lett 2007; 257:1.</a></li><li><a class="nounderline abstract_t">Bombski G, Gasiorowska A, Orszulak-Michalak D, et al. Elevated plasma gastrin, CEA, and CA 19-9 levels decrease after colorectal cancer resection. Int J Colorectal Dis 2003; 18:148.</a></li><li><a class="nounderline abstract_t">Smith AM, Watson SA. Review article: gastrin and colorectal cancer. Aliment Pharmacol Ther 2000; 14:1231.</a></li><li><a class="nounderline abstract_t">Orlando LA, Lenard L, Orlando RC. Chronic hypergastrinemia: causes and consequences. Dig Dis Sci 2007; 52:2482.</a></li><li><a class="nounderline abstract_t">Zuo Y, Jing Z, Bie M, et al. Association between Helicobacter pylori infection and the risk of colorectal cancer: A systematic review and meta-analysis. Medicine (Baltimore) 2020; 99:e21832.</a></li><li><a class="nounderline abstract_t">Bold RJ, Ishizuka J, Townsend CM Jr. Progress toward hormonal therapy of gastrointestinal cancer. Ann Surg 1996; 223:4.</a></li><li><a class="nounderline abstract_t">Stepan VM, Sawada M, Todisco A, Dickinson CJ. Glycine-extended gastrin exerts growth-promoting effects on human colon cancer cells. Mol Med 1999; 5:147.</a></li><li><a class="nounderline abstract_t">Litvak DA, Hellmich MR, Iwase K, et al. JMV1155: a novel inhibitor of glycine-extended progastrin-mediated growth of a human colon cancer in vivo. Anticancer Res 1999; 19:45.</a></li><li><a class="nounderline abstract_t">Kelly A, Hollande F, Shulkes A, Baldwin GS. Expression of progastrin-derived peptides and gastrin receptors in a panel of gastrointestinal carcinoma cell lines. J Gastroenterol Hepatol 1998; 13:208.</a></li><li><a class="nounderline abstract_t">Van Solinge WW, Nielsen FC, Friis-Hansen L, et al. Expression but incomplete maturation of progastrin in colorectal carcinomas. Gastroenterology 1993; 104:1099.</a></li><li><a class="nounderline abstract_t">Ciccotosto GD, McLeish A, Hardy KJ, Shulkes A. Expression, processing, and secretion of gastrin in patients with colorectal carcinoma. Gastroenterology 1995; 109:1142.</a></li><li><a class="nounderline abstract_t">Smith AM, Watson SA. Gastrin and gastrin receptor activation: an early event in the adenoma-carcinoma sequence. Gut 2000; 47:820.</a></li><li><a class="nounderline abstract_t">Ramamoorthy S, Stepan V, Todisco A. Intracellular mechanisms mediating the anti-apoptotic action of gastrin. Biochem Biophys Res Commun 2004; 323:44.</a></li><li><a class="nounderline abstract_t">Clarke PA, Dickson JH, Harris JC, et al. Gastrin enhances the angiogenic potential of endothelial cells via modulation of heparin-binding epidermal-like growth factor. Cancer Res 2006; 66:3504.</a></li><li><a class="nounderline abstract_t">Smith JP, Cao H, Edmondson EF, et al. Cholecystokinin-B Receptor-Targeted Nanoparticle for Imaging and Detection of Precancerous Lesions in the Pancreas. Biomolecules 2021; 11.</a></li><li><a class="nounderline abstract_t">Smith JP, Verderame MF, Zagon IS. Antisense oligonucleotides to gastrin inhibit growth of human pancreatic cancer. Cancer Lett 1999; 135:107.</a></li><li><a class="nounderline abstract_t">Smith JP, Shih A, Wu Y, et al. Gastrin regulates growth of human pancreatic cancer in a tonic and autocrine fashion. Am J Physiol 1996; 270:R1078.</a></li><li><a class="nounderline abstract_t">Mu G, Ding Q, Li H, et al. Gastrin stimulates pancreatic cancer cell directional migration by activating the Gα12/13-RhoA-ROCK signaling pathway. Exp Mol Med 2018; 50:1.</a></li><li><a class="nounderline abstract_t">Payne NA, Gerber JG. Differential effects of somatostatin and prostaglandins on gastric histamine release to pentagastrin. J Pharmacol Exp Ther 1992; 263:520.</a></li><li><a class="nounderline abstract_t">Machens A, Hauptmann S, Dralle H. Medullary thyroid cancer responsiveness to pentagastrin stimulation: an early surrogate parameter of tumor dissemination? J Clin Endocrinol Metab 2008; 93:2234.</a></li><li><a class="nounderline abstract_t">Băetu M, Olariu CA, Moldoveanu G, et al. Calcitonin Stimulation Tests: Rationale, Technical Issues and Side Effects: A Review. Horm Metab Res 2021; 53:355.</a></li><li><a class="nounderline abstract_t">Ahlman H, Dahlström A, Grönstad K, et al. The pentagastrin test in the diagnosis of the carcinoid syndrome. Blockade of gastrointestinal symptoms by ketanserin. Ann Surg 1985; 201:81.</a></li><li><a class="nounderline abstract_t">Modlin IM, Tang LH. Approaches to the diagnosis of gut neuroendocrine tumors: the last word (today). Gastroenterology 1997; 112:583.</a></li><li><a class="nounderline abstract_t">Boyce M, Moore AR, Sagatun L, et al. Netazepide, a gastrin/cholecystokinin-2 receptor antagonist, can eradicate gastric neuroendocrine tumours in patients with autoimmune chronic atrophic gastritis. Br J Clin Pharmacol 2017; 83:466.</a></li></ol></div><div id="topicVersionRevision">Topic 2551 Version 16.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31853955" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Gastric Peptides-Gastrin and Somatostatin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : On the chemical mechanism of gastric secretion</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14159395" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : THE CONSTITUTION AND PROPERTIES OF TWO GASTRINS EXTRACTED FROM HOG ANTRAL MUCOSA.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1373504" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Expression cloning and characterization of the canine parietal cell gastrin receptor.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9587068" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Processing of precursors of gastroenteropancreatic hormones: diagnostic significance.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9790570" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : The new biology of gastrointestinal hormones.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26344355" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : The effect of bariatric surgery on gastrointestinal and pancreatic peptide hormones.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26344355" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : The effect of bariatric surgery on gastrointestinal and pancreatic peptide hormones.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19172694" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : The art of measuring gastrin in plasma: a dwindling diagnostic discipline?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2859810" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Cholecystokinin potently releases somatostatin from canine fundic mucosal cells in short-term culture.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12688378" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Cellular localization of cholecystokinin receptors as the molecular basis of the periperal regulation of acid secretion.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16259739" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Genetic dissection of the signaling pathways that control gastric acid secretion.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8095036" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Gastrin secretion induced by distention is mediated by gastric cholinergic and vasoactive intestinal peptide neurons in rats.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1364124" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Neural, hormonal, and paracrine regulation of gastrin and acid secretion.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9276720" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Bombesin-induced gastrin release from canine G cells is stimulated by Ca2+ but not by protein kinase C, and is enhanced by disruption of rho/cytoskeletal pathways.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20876097" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Calcium-sensing receptor is a physiologic multimodal chemosensor regulating gastric G-cell growth and gastrin secretion.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7831396" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Gastric acid secretion.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Gastric enterochromaffin-like cells and the regulation of acid secretion</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35330921" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Gastrin: From Physiology to Gastrointestinal Malignancies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24100729" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Gastric secretion.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21392266" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Incretin physiology beyond glucagon-like peptide 1 and glucose-dependent insulinotropic polypeptide: cholecystokinin and gastrin peptides.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24019399" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Gastrin and D1 dopamine receptor interact to induce natriuresis and diuresis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9394759" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : How does Helicobacter pylori cause mucosal damage? Its effect on acid and gastrin physiology.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19491250" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : KCNQ1 is the luminal K+ recycling channel during stimulation of gastric acid secretion.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22805636" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Iron-deficiency anaemia, gastric hyperplasia, and elevated gastrin levels due to potassium channel dysfunction in the Jervell and Lange-Nielsen Syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9378553" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Differential expression of the CCK-A and CCK-B/gastrin receptor genes in human cancers of the esophagus, stomach and colon.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10228846" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Human pancreatic cancer cell lines express the CCKB receptor.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28560291" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Gastrin and Gastric Cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28980157" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Expression of the Cholecystokinin-B Receptor in Neoplastic Gastric Cells.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10861424" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Closing the gastrin loop in pancreatic carcinoma: coexpression of gastrin and its receptor in solid human pancreatic adenocarcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10913157" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Human colorectal cancers express a constitutively active cholecystokinin-B/gastrin receptor that stimulates cell growth.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9382052" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Fundic gland polyps developing during omeprazole therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10535874" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Human gastrin: a Helicobacter pylori--specific growth factor.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31963924" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Proton Pump Inhibitor Use, Hypergastrinemia, and Gastric Carcinoids-What Is the Relationship?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24279703" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : The regulation of gastric acid secretion - clinical perspectives.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8101501" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Is the multiple endocrine neoplasia type 1 gene a suppressor for fundic argyrophil tumors in the Zollinger-Ellison syndrome?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7762739" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Hypergastrinemia and gastric enterochromaffin-like cells.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14747767" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Multiple endocrine neoplasia type 1 and Zollinger-Ellison syndrome: a prospective study of 107 cases and comparison with 1009 cases from the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9797369" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Oncogenic ras induces gastrin gene expression in colon cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9378387" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Rectal cell proliferation and colon cancer risk in patients with hypergastrinaemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9679032" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Gastrin and colorectal cancer: a prospective study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17698287" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Role of gastrin peptides in carcinogenesis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12548418" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Elevated plasma gastrin, CEA, and CA 19-9 levels decrease after colorectal cancer resection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11012467" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Review article: gastrin and colorectal cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17415644" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Chronic hypergastrinemia: causes and consequences.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32925719" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Association between Helicobacter pylori infection and the risk of colorectal cancer: A systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8554417" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Progress toward hormonal therapy of gastrointestinal cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10404512" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Glycine-extended gastrin exerts growth-promoting effects on human colon cancer cells.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10226523" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : JMV1155: a novel inhibitor of glycine-extended progastrin-mediated growth of a human colon cancer in vivo.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10221825" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Expression of progastrin-derived peptides and gastrin receptors in a panel of gastrointestinal carcinoma cell lines.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8462798" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Expression but incomplete maturation of progastrin in colorectal carcinomas.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7557079" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Expression, processing, and secretion of gastrin in patients with colorectal carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11076881" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Gastrin and gastrin receptor activation: an early event in the adenoma-carcinoma sequence.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15351698" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Intracellular mechanisms mediating the anti-apoptotic action of gastrin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16585174" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Gastrin enhances the angiogenic potential of endothelial cells via modulation of heparin-binding epidermal-like growth factor.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34944412" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Cholecystokinin-B Receptor-Targeted Nanoparticle for Imaging and Detection of Precancerous Lesions in the Pancreas.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10077228" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Antisense oligonucleotides to gastrin inhibit growth of human pancreatic cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8928909" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Gastrin regulates growth of human pancreatic cancer in a tonic and autocrine fashion.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29717112" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Gastrin stimulates pancreatic cancer cell directional migration by activating the Gα12/13-RhoA-ROCK signaling pathway.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1279159" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Differential effects of somatostatin and prostaglandins on gastric histamine release to pentagastrin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18364379" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Medullary thyroid cancer responsiveness to pentagastrin stimulation: an early surrogate parameter of tumor dissemination?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34154026" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Calcitonin Stimulation Tests: Rationale, Technical Issues and Side Effects: A Review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2578277" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : The pentagastrin test in the diagnosis of the carcinoid syndrome. Blockade of gastrointestinal symptoms by ketanserin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9024313" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Approaches to the diagnosis of gut neuroendocrine tumors: the last word (today).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27704617" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Netazepide, a gastrin/cholecystokinin-2 receptor antagonist, can eradicate gastric neuroendocrine tumours in patients with autoimmune chronic atrophic gastritis.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
